Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech company that develops anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies to treat cancer and organ fibrosis. Its pipeline includes candidates such as ALE.P02 for squamous cancers and lixudebart for fibrosis, which target exposed Claudin-1 to block disease signaling and kill tumor cells. The company focuses on unlocking the therapeutic potential of the Claudin-1 target to address unmet needs in oncology and fibrotic diseases.
Visit websiteAllschwil, Switzerland
Biotechnology
Healthcare
Oncology
Pharmaceuticals
Funding summary
- Total raised
- €11.2M
- Funding rounds
- 1
Investors in Alentis Therapeutics
Investors on record for Alentis Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Alentis Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors